S. Seiler

发表

S. Loibl, S. Seiler, 2020, Breast Cancer in Young Women.

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.

P. Fasching, A. Schneeweiss, C. Denkert, 2022, JAMA oncology.

Impact in delay of start of chemotherapy and surgery on pCR and survival in breast cancer: A pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials.

P. Fasching, A. Schneeweiss, C. Denkert, 2017 .

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study

C. Denkert, F. Marmé, S. Loibl, 2022, Breast.

Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, European journal of cancer.

Adverse Event Management of Oral Mucositis in Patients with Breast Cancer

S. Loibl, C. Jackisch, S. Seiler, 2014, Breast Care.

Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.

A. Schneeweiss, P. Neven, S. Loibl, 2021, European journal of cancer.

Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.

S. Loibl, J. Unger, M. Ceppi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).

P. Fasching, A. Schneeweiss, C. Denkert, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group

P. Campbell, C. Sotiriou, S. Loi, 2017, npj Breast Cancer.

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, The Lancet. Oncology.

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC).

S. Loi, L. Carey, S. Mandrekar, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history

A. Meindl, R. Schmutzler, M. Kiechle, 2018, BMC Cancer.

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)

F. Marmé, S. Loibl, V. Nekljudova, 2019, Anti-cancer drugs.

Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial.

F. Marmé, S. Loibl, M. Untch, 2021, JAMA oncology.

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Sung-Bae Kim, C. Denkert, K. Gelmon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial

P. Fasching, A. Schneeweiss, C. Denkert, 2020, Journal of the American Heart Association.

Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials.

P. Fasching, A. Schneeweiss, C. Denkert, 2020, European journal of cancer.

Abstract GS4-01: Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients

S. Loibl, J. Unger, M. Ceppi, 2018 .

NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

C. Denkert, J. Costantino, C. Geyer, 2018 .

Impact in delay of starting chemotherapy and surgery on pCR/survival in breast cancer (BC)-pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials

A. Schneeweiss, S. Loibl, V. Nekljudova, 2017, Senologie - Zeitschrift für Mammadiagnostik und -therapie.

Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients.

F. Marmé, S. Loibl, V. Nekljudova, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract PD7-10: Male-GBG54: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients

F. Marmé, S. Loibl, V. Nekljudova, 2018 .

The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group

P. Campbell, C. Sotiriou, S. Loi, 2017, npj Breast Cancer.

168MO GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status

A. Schneeweiss, C. Denkert, S. Loibl, 2020 .

GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

C. Denkert, S. Loibl, V. Nekljudova, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history

A. Meindl, R. Schmutzler, M. Kiechle, 2018, BMC Cancer.

Edinburgh Research Explorer Gonadotropin-releasing hormone analogs during chemotherapy for preservation of ovarian function and fertility in premenopausal early breast cancer patients: a systematic review and meta-analysis of individual patient-level data

M. Ceppi, K. Albain, M. Lambertini, 2018 .

Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B

Sung-Bae Kim, C. Denkert, K. Gelmon, 2021 .